精鼎医药在WCG CenterWatch全球研究中心关系调研中被评为 "值得合作的CRO"

2022-01-18 精鼎医药 精鼎医药

随着整个药物开发过程中的不断发展和创新,临床试验中心、申办方和CRO必须更加紧密地合作,以加强整体参与度,改善患者的临床试验体验。

2022年1月18日,精鼎医药(Parexel),一家领先的、致力于开发和提供创新疗法,以改善人类健康的跨国临床研究组织(CRO),在2021年WCG CenterWatch全球研究中心关系调研中被研究中心评为 "最值得合作的CRO"。一年两度的WCG CenterWatch调研旨在探讨临床试验中心、申办方和CRO之间的关系,并对整体表现进行深入分析。

针对研究中心与CRO的关系,2021年的调研设立了35项最受研究中心重视的表现标准,并要求受访者对参与评选的CRO进行评估。在6个大类的35个表现标准中,精鼎医药以「卓越」的最高评分在所有参与调研的29家CRO中脱颖而出。此外,精鼎医药在行业声誉和直接工作关系质量方面同时排名前五,是仅有的获此殊荣的两家公司之一,更是在行业总体声誉中赢得了研究中心的青睐并荣获第四。调研中的杰出成绩凸显了公司孜孜不倦的深耕与投入,以支持研究中心为患者提供优质服务。

精鼎医药首席患者官克莱尔·格雷斯(Clare Grace)博士表示:“随着我们在整个药物开发过程中的不断发展和创新,临床试验中心、申办方和CRO必须更加紧密地合作,以加强整体参与度,改善患者的临床试验体验。精鼎医药理解并高度重视研究中心在这个过程中发挥的关键作用。此次被评为最佳CRO之一,进一步表明了我们的全球团队对发展和培养强大的研究中心关系的坚定承诺。这种合作关系将确保研究的快速启动和顺利进行,并最终改善试验体验,从而将重要的治疗方案更快地带给有需求的患者。同时,在过去两年新型冠状病毒肺炎带来巨大挑战的背景下,这一认可对我们而言意味着更多。”

一年两度的全球研究中心关系调研由WCG CenterWatch发起(1997年首次推出),此次调研于2021年8月11日至9月22日在线上举行。调研问题设计基于北美、南美、欧洲、亚太和非洲的研究中心、申办方和CRO的建议,在全球范围内邀请了6万多名研究中心代表参与,最终回收到约3,700份问卷。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-01-20 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1665393, encodeId=00531665393a2, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Wed Jan 19 17:24:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857998, encodeId=db54185e99828, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Sep 24 12:24:16 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950421, encodeId=74141950421a1, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Thu Jul 07 06:24:16 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751502, encodeId=e8651e515027a, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Sun Nov 27 19:24:16 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410193, encodeId=1b26141019301, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602714, encodeId=cccd1602e1404, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Thu Jan 20 01:24:16 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-01-20 bsmagic9138